Bispecific Antibody Combinations In Relapsed Refractory Multiple Myeloma: RedirecTT-1 Follow-Up

Opinion
Video

Panelists discuss how the follow-up results from the RedirecTT-1 study provide insights into the long-term efficacy and safety of bispecific antibody combinations in treating relapsed/refractory multiple myeloma, potentially shaping future treatment approaches for this challenging disease.

Recent Videos
9 Experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
9 Experts are featured in this series.